Clinical Trial with Nimesulide,a New Non-Steroid Anti-Inflammatory Agent,in Rheumatic Pathology

Abstract

The author reports the use of a new non-steroid drug, endowed with anti-inflammatory, analgesic and antipyretic activities (Nimesulide) in seventy patients affected with a subacute or chronic rheumatic pathology.

Nimesulide, given orally at a dosage of 200–600 mg daily for a mean duration of 26 days, induced either the resolution of the condition or a clinically useful improvement in 86% of the patients, with a low incidence of untoward side-effects characterized by a prevailing gastric localization.